Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ASH 2018

Videos
News
Characterisation of novel subtypes in B progenitor acute lymphoblastic leukaemia
Dr Zhaohui Gu - St. Jude Children's Research Hospital, Memphis, USA
Characterisation of novel subtypes in B progenitor acute lymphoblastic leukaemia ( Dr Zhaohui Gu - St. Jude Children's Research Hospital, Memphis, USA )
19 Dec 2018
Bispecific CD19/22 CAR therapy in children and young adults with ALL
Dr Liora M Schultz - Stanford University, Palo Alto, USA
Bispecific CD19/22 CAR therapy in children and young adults with ALL ( Dr Liora M Schultz - Stanford University, Palo Alto, USA )
17 Dec 2018
Checkpoint blockade therapy may sensitise non-Hodgkin lymphoma to subsequent...
Dr Nicole Carreau - NYU Langone Health, New York, USA
Checkpoint blockade therapy may sensitise non-Hodgkin lymphoma to subsequent therapy ( Dr Nicole Carreau - NYU Langone Health, New York, USA )
17 Dec 2018
Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone...
Dr Mark Bustoros - Harvard Medical School, Boston, USA
Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smouldering multiple myeloma ( Dr Mark Bustoros - Harvard Medical School, Boston, USA )
17 Dec 2018
Indoximod combined with chemotherapy in newly diagnosed AML patients
Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA
Indoximod combined with chemotherapy in newly diagnosed AML patients ( Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA )
17 Dec 2018
Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL
Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA
Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL ( Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA )
17 Dec 2018
Phase II trial of nivolumab combined with ibrutinib for patients with Richter...
Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA
Phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation ( Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA )
17 Dec 2018
CAR-T cell dosing approaches in treating acute lymphoblastic leukaemia
Prof Bijal Shah - H. Lee Moffitt Cancer Centre & Research Institute, Tampa, USA
CAR-T cell dosing approaches in treating acute lymphoblastic leukaemia ( Prof Bijal Shah - H. Lee Moffitt Cancer Centre & Research Institute, Tampa, USA )
17 Dec 2018
Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemia
Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona...
Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemia ( Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )
17 Dec 2018
Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed...
Dr Habte Yimer - Texas Oncology, Tyler, USA
Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )
17 Dec 2018
Blinatumomab as second salvage therapy in adults with relapsed/refractory...
Prof Alessandro Rambaldi - University of Milan, Milan, Italy
Blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-NHL ( Prof Alessandro Rambaldi - University of Milan, Milan, Italy )
13 Dec 2018
Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative...
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative disorder in the central nervous system ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
13 Dec 2018
Results from the EMN-011 trial, combination therapy for multiple myeloma
Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
Results from the EMN-011 trial, combination therapy for multiple myeloma ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )
13 Dec 2018
Maintenance therapy with the oral PI ixazomib significantly prolongs PFS...
Dr Francesca Gay - University of Torino, Torino, Italy
Maintenance therapy with the oral PI ixazomib significantly prolongs PFS following ASCT in multiple myeloma ( Dr Francesca Gay - University of Torino, Torino, Italy )
13 Dec 2018
Efficacy and safety of KRd or KCd induction in multiple myeloma
Dr Francesca Gay - University of Torino, Torino, Italy
Efficacy and safety of KRd or KCd induction in multiple myeloma ( Dr Francesca Gay - University of Torino, Torino, Italy )
13 Dec 2018
Clinical impact of an accurate genetic characterisation of older AML patients
Prof Alessandro Rambaldi - University of Milan, Milan, Italy
Clinical impact of an accurate genetic characterisation of older AML patients ( Prof Alessandro Rambaldi - University of Milan, Milan, Italy )
13 Dec 2018
Two clinical trials using combination therapy in adult patients with multiple...
Dr Irene M. Ghobrial - Dana-Farber Cancer Institute, Boston, USA
Two clinical trials using combination therapy in adult patients with multiple myeloma ( Dr Irene M. Ghobrial - Dana-Farber Cancer Institute, Boston, USA )
12 Dec 2018
The combined analysis of carfilzomib trials for multiple myeloma
Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain
The combined analysis of carfilzomib trials for multiple myeloma ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )
7 Dec 2018
Gilteritinib combined with induction and consolidation chemotherapy in newly...
Dr Keith Pratz - Johns Hopkins University, Baltimore, USA
Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients ( Dr Keith Pratz - Johns Hopkins University, Baltimore, USA )
6 Dec 2018
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline...
Dr Lorenz Trümper - Georg August University, Göttingen, Germany
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas ( Dr Lorenz Trümper - Georg August University, Göttingen, Germany )
6 Dec 2018
Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor...
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapsed/refractory ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
6 Dec 2018
Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for...
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for children with acute leukaemia ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
6 Dec 2018
Matched targeted therapy for paediatric patients with relapsed, refractory or...
Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA
Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias ( Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA )
6 Dec 2018
Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )
6 Dec 2018
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed...
Prof Marion Subklewe - University of Munich, Munich, Germany
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML ( Prof Marion Subklewe - University of Munich, Munich, Germany )
6 Dec 2018
KRd versus VRd in patients with newly diagnosed multiple myeloma
Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA
KRd versus VRd in patients with newly diagnosed multiple myeloma ( Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA )
6 Dec 2018
Ibrutinib and rituximab provides superior PFS and OS compared to FCR for...
Dr Tait Shanafelt - Standford University, Stanford, USA
Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL ( Dr Tait Shanafelt - Standford University, Stanford, USA )
6 Dec 2018
Daratumumab increases PFS in patients with transplant-ineligible multiple...
Prof Thierry Facon - Hôpital Claude Huriez, Lille, France
Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )
6 Dec 2018
Researchers identify mutation that causes resistance to venetoclax in CLL...
Dr Piers Blombery - University of Melbourne, Melbourne, Australia
Researchers identify mutation that causes resistance to venetoclax in CLL patients ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )
6 Dec 2018
Daratumumab found to increase PFS in patients with transplant-ineligible newly...
Prof Thierry Facon - Hôpital Claude Huriez, Lille, France
Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )
4 Dec 2018
Ibrutinib-based therapy superior for younger patients with previously untreated...
Dr Tait Shanafelt - Stanford University, Stanford, USA
Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care ( Dr Tait Shanafelt - Stanford University, Stanford, USA )
4 Dec 2018
Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy
Dr Alok Khorana - Cleveland Clinic, Cleveland, USA
Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy ( Dr Alok Khorana - Cleveland Clinic, Cleveland, USA )
4 Dec 2018
Resistance mechanisms to venetoclax in patients with progressive CLL
Dr Piers Blombery - University of Melbourne, Melbourne, Australia
Resistance mechanisms to venetoclax in patients with progressive CLL ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )
4 Dec 2018
Patient treatment preferences in relapsed/refractory multiple myeloma
Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos
Patient treatment preferences in relapsed/refractory multiple myeloma ( Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos )
3 Dec 2018
Landscape change with oral proteasome maintenance in multiple myeloma patients
Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar...
Landscape change with oral proteasome maintenance in multiple myeloma patients ( Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lonial )
3 Dec 2018
The importance of NF-kB pathway in myeloma
Dr Nizar Bahlis - University of Calgary, Calgary, Canada
The importance of NF-kB pathway in myeloma ( Dr Nizar Bahlis - University of Calgary, Calgary, Canada )
3 Dec 2018
Multiple myeloma highlights and more from ASH 2018
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Multiple myeloma highlights and more from ASH 2018 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
3 Dec 2018
Results of the Beat AML umbrella study for previously untreated acute myeloid...
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )
3 Dec 2018
An integrated view of the role of the B cell antigen receptor in lymphoma cell...
Dr Stefano Casola - Institute of Molecular Oncology Foundation, Milan, Italy
An integrated view of the role of the B cell antigen receptor in lymphoma cell fitness ( Dr Stefano Casola - Institute of Molecular Oncology Foundation, Milan, Italy )
3 Dec 2018
Myeloma XI study: Quadruplet regimen for transplant eligible patients
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Myeloma XI study: Quadruplet regimen for transplant eligible patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
3 Dec 2018
Developments in CAR T treatments for adult patients
Dr David Miklos - Stanford University, Palo Alto, USA
Developments in CAR T treatments for adult patients ( Dr David Miklos - Stanford University, Palo Alto, USA )
3 Dec 2018
Outcomes for patients with disease progression following CD19-specific CAR T...
Dr Victor Chow - Fred Hutchinson Cancer Research Centre, Seattle, USA
Outcomes for patients with disease progression following CD19-specific CAR T-cell therapy ( Dr Victor Chow - Fred Hutchinson Cancer Research Centre, Seattle, USA )
3 Dec 2018
ASH 2018: Expert overview of the latest in CLL, ALL and AML
Prof Robin Foa - University of Rome, Rome, Italy
ASH 2018: Expert overview of the latest in CLL, ALL and AML ( Prof Robin Foa - University of Rome, Rome, Italy )
3 Dec 2018
Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients
Dr Stephan Grupp - Children's Hospital of Philadelphia, Philadelphia, USA
Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients ( Dr Stephan Grupp - Children's Hospital of Philadelphia, Philadelphia, USA )
2 Dec 2018
Determining the prognosis of patients with myelodysplastic syndromes using...
Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA
Determining the prognosis of patients with myelodysplastic syndromes using machine learning ( Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA )
2 Dec 2018
The benefits of a stem cell transplant after CAR T-cell therapy in paediatric...
Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA
The benefits of a stem cell transplant after CAR T-cell therapy in paediatric patients ( Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA )
2 Dec 2018
Long term data from JULIET trial, using tisagenlecleucel for patients with...
Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland...
Long term data from JULIET trial, using tisagenlecleucel for patients with relapsed or treatment-resistant DLBCL ( Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, USA )
2 Dec 2018
ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T...
Dr Owen O'Connor - Columbia University Medical Centre, New York, USA
ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )
2 Dec 2018
ECHELON-2: a large peripheral T-cell lymphoma trial
Dr Owen O'Connor - Columbia University Medical Centre, New York, USA
ECHELON-2: a large peripheral T-cell lymphoma trial ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )
2 Dec 2018
Link between gut microbiota and haematopoietic cell transplantation outcomes
Dr Jonathan Peled - Memorial Sloan Kettering Cancer Centre, New York, USA
Link between gut microbiota and haematopoietic cell transplantation outcomes ( Dr Jonathan Peled - Memorial Sloan Kettering Cancer Centre, New York, USA )
2 Dec 2018
Initial report of the Beat AML umbrella study for previously untreated AML
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
Initial report of the Beat AML umbrella study for previously untreated AML ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )
2 Dec 2018
Machine learning algorithm improves prognosis accuracy for patients with...
Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA
Machine learning algorithm improves prognosis accuracy for patients with myelodysplastic syndromes ( Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA )
2 Dec 2018
Diversity of gut microbiota linked with complications from haematopoietic cell...
Dr Jonathan Peled - Memorial Sloan Kettering Cancer Centre, New York, USA
Diversity of gut microbiota linked with complications from haematopoietic cell transplantation ( Dr Jonathan Peled - Memorial Sloan Kettering Cancer Centre, New York, USA )
2 Dec 2018
Progression-free survival milestones in primary central nervous system lymphoma
Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark
Progression-free survival milestones in primary central nervous system lymphoma ( Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark )
2 Dec 2018
Relapse risk and loss in expectation of lifetime in young classical hodgkin...
Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark
Relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients ( Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark )
2 Dec 2018
New therapies for transfusion dependent MDS patients
Dr Alan List - Moffitt Cancer Centre, Tampa, USA
New therapies for transfusion dependent MDS patients ( Dr Alan List - Moffitt Cancer Centre, Tampa, USA )
2 Dec 2018
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma
Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma ( Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany )
1 Dec 2018
Inhibiting the immune system’s natural response may boost benefits and...
Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA
Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy ( Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA )
1 Dec 2018
Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell...
Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA
Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL ( Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA )
1 Dec 2018
Ibrutinib alone and in combination with rituximab for older patients with...
Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre...
Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia ( Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre, Columbus, USA )
1 Dec 2018
Stem cell transplant after CAR T-cell therapy reduces relapses in acute...
Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA
Stem cell transplant after CAR T-cell therapy reduces relapses in acute lymphocytic leukaemia ( Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA )
1 Dec 2018
CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia
Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA
CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia ( Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA )
1 Dec 2018
Latest results from JULIET: Tisagenlecleucel in adults with DLBCL
Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland...
Latest results from JULIET: Tisagenlecleucel in adults with DLBCL ( Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, USA )
1 Dec 2018
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute...
Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia ( Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA )
1 Dec 2018
Latest analysis of the ELIANA trial for acute lymphocytic leukaemia
Dr Stephan Grupp - University of Pennsylvania, Philadelphia, USA
Latest analysis of the ELIANA trial for acute lymphocytic leukaemia ( Dr Stephan Grupp - University of Pennsylvania, Philadelphia, USA )
1 Dec 2018
Four cycles of chemotherapy as effective as six for diffuse large B-Cell...
Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany
Four cycles of chemotherapy as effective as six for diffuse large B-Cell lymphoma ( Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany )
1 Dec 2018
Results from the MEDALIST trial for patients with anaemia in MDS
Dr Alan List - Moffitt Cancer Center, Tampa, USA
Results from the MEDALIST trial for patients with anaemia in MDS ( Dr Alan List - Moffitt Cancer Center, Tampa, USA )
1 Dec 2018
Ibrutinib outperforms chemoimmunotherapy in older patients with chronic...
Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Center...
Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukaemia ( Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
1 Dec 2018
Luspatercept reduces need for blood transfusions in beta thalassemia and MDS
Dr Maria Domenica Cappellini - University of Milan, Milan, Italy
Luspatercept reduces need for blood transfusions in beta thalassemia and MDS ( Dr Maria Domenica Cappellini - University of Milan, Milan, Italy )
1 Dec 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation